Trials / Completed
CompletedNCT02760498
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 432 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cemiplimab |
Timeline
- Start date
- 2016-04-07
- Primary completion
- 2023-10-18
- Completion
- 2023-10-18
- First posted
- 2016-05-03
- Last updated
- 2025-05-28
- Results posted
- 2024-12-11
Locations
78 sites across 8 countries: United States, Australia, Brazil, France, Germany, Greece, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02760498. Inclusion in this directory is not an endorsement.